“We believe that the HiSeq 2000s will significantly increase our capabilities in high-throughput genomics, as our experience with early access instruments has already produced multiple runs in excess of 250 Gb of data and yielded significant improvements in lab workflow,” remarks Robert Nicol, Ph.D., director of sequencing operations and technology development at the Broad Institute. “Coupled with Illumina's newest sequencing chemistry, the system has the potential to increase high-quality base yields at longer read lengths and could help improve mapping accuracy and variant discovery.”

The compatibility of HiSeq 2000 sample preparation and data analysis with that of the Genome Analzyer IIx system allows organizations to seamlessly introduce the HiSeq systems into their existing sequencing infrastructures, Illumina asserts. The HiSeq 2000 sequencing system leverages Illumina's reversible terminator-based sequencing by synthesis chemistry in combination.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.